Reviewer’s report

Title: The endogenous soluble VEGF Receptor-2 isoform suppresses lymph node and lung metastases in a mouse immunocompetent mammary cancer model

Version: 1 Date: 31 July 2010

Reviewer: Airo TSUBURA

Reviewer’s report:

GENERAL COMMENTS:
The authors have shown endogenous soluble VEGF Receptor-2 (esVEGFR-2) was effective suppressing the growth of primary tumor growth and the lymph node and/or lung metastasis of BJMC3879luc2 mouse mammary carcinoma cells. The cancer suppressing mechanisms was through decreased lymphatic vessels (but not blood microvessels) and decreased tumor proliferating rate (but not increased apoptotic rate) caused by esVEGFR-2, and concluded that esVEGFR-2 may be one of the candidate for the treatment of metastatic breast cancer. The experiments are well performed, the results are clear, thus the reviewer think that this manuscript is acceptable to BMC Medicine. However, several points described below should be considered before publication.

DETAILED COMMENTS:
1. Do BJMC3879luc2 cells express VEGF-C?
2. Are there any difference between Lyve-1 and podoplanin to localize lymph vessels?
3. Several mistypings are seen in the Text.
4. Also, check Fig. 3 again.
5. Some references do not fit the journal style.

Which journal?: Appropriate or potentially appropriate for BMC Medicine: an article of importance in its field

What next?: Accept for publication in BMC Medicine after minor essential revisions

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests